Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Department of Pediatrics, |
RCV000791248 | SCV000925968 | pathogenic | Glycogen storage disease, type II | 2019-07-10 | no assertion criteria provided | clinical testing | This sequence change replaces leucine with arginine at codon 632 of the GAA protein (p.L632R). This variant is absent at least 340 control alleles (100 alleles studied by PCR-restriction digest and 240 alleles based on our in-house whole exome database). This variant has not been reported in the literature in individuals with GAA-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, Polyphen-2, PredictSNP2, CADD, DANN, FATHMM, and FunSeq2) all suggest that this variant is damaging/deleterious. In vitro expression analysis of c.1895T>G (p.L632R) indicates that this variant leads to approximately 99% loss of enzyme activity and prohibited secretion of the precursor form completely. Based on 3D structure available (PDB: 5NN8), the p.L632 residue is situated in helix 6 (the helix between the sixth and seventh beta strands of the (beta/alpha)8 structure of the catalytic domain and is packed against the proximal b-sheet domain. It is in a hydrophobic environment, surrounded by the side chains of p.V628, p.L636, p.A724, p.P726 and p.L744; therefore, replacing the nonpolar leucine side chain with the highly polar, charged arginine side chain is expected to disrupt the hydrophobic packing of the protein, thereby explaining the lack of enzyme activity. In summary, due to the available evidence, we interpret this variant has been classified as Pathogenic. |